Compare

AstraZeneca/£AZN

1D1W1M3M6MYTD1Y5YMAX

About AstraZeneca

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Ticker
£AZN
Sector
Health
Primary listing
LSE
Employees
96,100

AstraZeneca Metrics

BasicAdvanced
£206B
24.70
£5.39
0.16
£2.39
1.80%

What the Analysts think about AstraZeneca

Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
Analyst projections of the future price of AstraZeneca stock.

Bulls say / Bears say

In the first nine months of 2026, revenue rose 7% and core EPS rose 14%; AstraZeneca kept its full-year growth guidance. That shows it is still converting demand into earnings despite pressure on older medicines. (AstraZeneca)
Oncology, respiratory and immunology, and rare disease all delivered double-digit growth in the first nine months. Strength across several businesses makes growth less dependent on a single therapy area. (AstraZeneca)
AstraZeneca reported 12 positive Phase III readouts this year, with combined peak annual sales potential above $10 billion, and 47 approvals in major regions. These developments could supply new medicines to support growth beyond current launches. (AstraZeneca)
Farxiga and Brilinta are facing loss-of-exclusivity pressure, while China’s volume-based procurement scheme is also weighing on sales. AstraZeneca says growth in other areas is currently offsetting these headwinds, but they remain a drag on the portfolio. (AstraZeneca)
Recent trial setbacks expose the risk in relying on pipeline medicines for future growth: Etcamah missed its main goal in a late-stage breast-cancer trial, and AstraZeneca stopped a volrustomig lung-cancer trial after it was unlikely to meet its main goals. Further failures could weaken confidence in the pipeline. (Reuters, Reuters)
Higher investment and restructuring costs could weigh on cash generation: the company expects up to $2 billion in one-off restructuring costs, while net debt rose to $25.8 billion by the end of September. The planned savings may take time to offset those costs. (AstraZeneca, Proactive Investors)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.

AstraZeneca Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

AstraZeneca Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing AstraZeneca

AllEURGBPUSD
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.